A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301 Meeting Abstract
| Authors: | Grisham, R.; Monk, B.; Van Nieuwenhuysen, E.; Moore, K.; Fabbro, M.; O'Malley, D.; Oaknin, A.; Thaker, P.; Oza, A.; Colombo, N.; Lustgarten, S.; Youssoufian, H.; Banerjee, S. |
| Abstract Title: | A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301 |
| Meeting Title: | IGCS 2024 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 34 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2024 Oct 16-18 |
| Meeting Location: | Dublin, Ireland |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2024-10-01 |
| Start Page: | A53 |
| End Page: | A54 |
| Language: | English |
| ACCESSION: | WOS:001443829100008 |
| DOI: | 10.1136/ijgc-2024-IGCS.71 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PR029/#943 -- Source: Wos |
